



ORIGINAL RESEARCH PAPER

Clinical Microbiology

INSIGHTS INTO BIOFILM DYNAMICS, RESISTANCE MECHANISMS, AND CONTROL STRATEGIES

KEY WORDS: Biofilm, Healthcare-Associated Infection, Medical Device Infections, Antibiotic Resistance, Biofilm Control

Dr. Gulfishan

MBBS, Junior Resident in microbiology

Dr. Vandana Verma

MD, DHA, HOD & Professor, Department of microbiology, CMC Ludhiana

ABSTRACT

Biofilms represent intricate assemblies of diverse microbial species, displaying impressive resistance against antibiotics and hostile conditions. In human bacterial infections, biofilms confer significant advantages to bacteria, largely due to the extracellular polymeric substances that provide structural support to these microbial communities. Notably, bacteria residing within biofilms demonstrate heightened antibiotic resistance compared to their solitary counterparts. Targeting biofilm formation by modulating quorum sensing mechanisms offers a promising approach to alleviate biofilm-related complications. The presence of biofilms on medical devices can compromise implant functionality and exacerbate patient health issues, surpassing mere device-related concerns. Vital strategies to combat biofilms involve disrupting enzymes and interfering with quorum-sensing pathways. By mimicking pivotal auto-inducers crucial for quorum sensing, inhibitors prevent their interaction with receptors, thereby effectively hindering biofilm formation.

Deciphering the Dynamics of Biofilm Formation

A biofilm represents a cooperative gathering of microorganisms that adhere to each other and commonly to a surface. These adherent cells generate a matrix of extracellular polymeric substances (EPSs), creating a dense environment. Predominantly consisting of water (up to 97%), microbial cells, polysaccharides, proteins, DNA, RNA, and ions, biofilms attach themselves to various surfaces, including medical equipment such as catheters, intrauterine contraceptive devices, prosthetic implants, cardiac valves, dental materials, and contact lenses.

Originally, biofilms were defined as bacterial communities attached to surfaces covered in a glycocalyx matrix. Over time, this definition expanded to encompass not only observable traits, such as cells firmly affixed to surfaces within an extracellular polymeric matrix, but also physiological features like altered growth rates and diverse gene expression among these organisms. The study of microbial biofilms can be traced back to Van Leeuwenhoek's use of simple microscopes to observe microorganisms on tooth surfaces, marking the early stages of investigation.

The term "biofilm" was coined by Bill Costerton in 1978. However, an understanding of biofilm infections and their medical importance began to emerge in the early 1970s with the detection of *Pseudomonas aeruginosa* cells in the sputum and lung tissue of chronically infected cystic fibrosis patients. The incorporation of the term "biofilm" into medical terminology occurred in 1985, credited to J.W.

Composition and Dynamics of Biofilms

Biofilms typically consist of 10% microbial mass and 90% water. Polysaccharides constitute 50% to 90% of the organic component, forming a dense mesh-like structure within the biofilm matrix. The hydroxyl groups on polysaccharide molecules enhance mechanical strength by promoting interactions between them. Additionally, biofilm architecture often includes positively charged ions such as Ca²⁺ or Mg²⁺, which form supportive cross-bridges between polymers, allowing biofilms to expand to thicknesses of up to 300 µm.

Bacteria thriving within biofilms exhibit stationary behavior and perform essential roles in various physiological processes within the biofilm environment. These sessile bacterial communities display distinct growth patterns, gene expression, transcription, and translation rates. These functional traits emerge as the sessile bacterial biofilm communities adapt to microenvironments characterized by

elevated osmolarity, limited nutrient availability, and heightened cell density. Consequently, biofilms exhibit an exceedingly viscoelastic structure with rubber-like behavior. Common bacteria found in biofilms include *Pseudomonas aeruginosa*, *Staphylococcus epidermidis*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Streptococcus viridans*, *Staphylococcus aureus*, and *Enterococcus faecalis*.

Exploring the Complexity of Biofilm Formation

Biofilm formation represents a complex process involving the transition of bacteria from free-swimming planktonic form to sessile biofilm-making form. External conditions such as temperature, pH, gravitational forces, hydrodynamic forces, Brownian movements, surface characteristics, quorum sensing, secondary messengers, and other signaling molecules influence this entire process.

The process of biofilm formation can be divided into four major stages:

1. **Attachment:** Biofilm formation begins with the attachment of planktonic microorganisms to surfaces, a critical step in the development of organized community structures. During this initial stage, microorganisms loosely and reversibly adhere to surfaces, with polarly attached microorganisms being characteristic.
2. **Growth or Microcolony Formation:** Following successful attachment, microorganisms proliferate and aggregate within self-produced EPS, leading to the formation of microcolonies in the presence of a high concentration of c-di-GMP.
3. **Maturation:** EPS plays a crucial role in biofilm maturation by facilitating microbial attachment to surfaces, stabilizing the 3-D structure of the biofilm, grouping cells, and providing protection against various stresses such as host immune responses, antimicrobials, oxidative damage, and metallic cations. Mature biofilms may develop a "mushroom" or "tower" shape structure, with microorganisms arranged based on aero-tolerance and metabolism rate.
4. **Dispersion:** Mature biofilms eventually rupture actively (through motility and EPS degradation-dependent dispersion) or passively (due to physical factors like liquid flow-dependent dispersion) to disperse microorganisms and initiate a new biofilm formation cycle. Factors contributing to the dispersion of mature biofilms include population overgrowth, intense competition, and nutrient depletion.

Multifaceted Pathogenic Mechanisms of Biofilms

Numerous pathogenic mechanisms of biofilms have been suggested, including:

- Facilitation of attachment to solid surfaces.
- Utilization of a "division of labor" to enhance metabolic efficiency within the community.
- Evasion of host defenses, such as phagocytosis.
- Attainment of a high density of microorganisms.
- Exchange of genes, potentially leading to the emergence of more virulent strains.
- Production of a substantial concentration of toxins.
- Provision of protection from antimicrobial agents.
- Transmission of microorganisms to other sites through the detachment of microbial aggregates.

Exploring the Diverse Applications of Biofilms

1. Environmental Applications of Biofilms:


Biofilms are implicated in approximately 60% of all food-borne outbreaks, underscoring the importance of understanding their diverse nature across various industries such as fresh produce, dairy, meat and fish processing, seafood, fermentation, and brewing. Ensuring food safety at every stage, from production to distribution, necessitates effective biofilm control. This highlights the urgency for further research in food microbiology. Common pathogens in the food industry include *Escherichia coli*, *Bacillus cereus*, *Campylobacter jejuni*, *Yersinia enterocolitica*, *Listeria monocytogenes*, and certain species of *Staphylococcus* and *Salmonella*.

Biofilms also contribute positively to the fermentation process. Microbial communities present in fermented food items, such as beers, wines, distillates, meats, fishes, cheeses, and breads, are encapsulated within the biofilm and benefit from the favorable growth conditions provided by extracellular polymeric substances (EPS).

Moreover, biofilm-based water treatment plants offer cost-effective and energy-efficient solutions for water treatment.

2. Biofilm in healthcare

Can be categorized under device-associated or tissue-associated biofilm infections



The microbes associated with the biofilm are listed below.

Disease	Pathogens
Urinary tract infection	<i>E. coli</i> , <i>Klebsiella pneumoniae</i> , <i>Proteus mirabilis</i> , <i>Pseudomonas aeruginosa</i> , <i>Staphylococcus</i> (<i>S. aureus</i> , <i>S. saprophyticus</i> , <i>S. epidermidis</i>), <i>Enterococci</i> , <i>Streptococci agalactiae</i> , <i>Corynebacterium urealyticum</i> , <i>Candida</i>
Oral health problems (dental plaques, dental caries, periodontitis)	<i>Neisseria</i> , <i>Streptococcus</i> , <i>Actinomyces</i> , <i>Veillonella</i>
Nosocomial infections (healthcare-acquired infections)	<i>Staphylococcus epidermidis</i> , <i>Candida albicans</i> , <i>Staphylococcus aureus</i> ,

Nosocomial infections (healthcare-acquired infections)	<i>P. aeruginosa</i> , <i>Klebsiella pneumoniae</i> , <i>Enterococcus faecalis</i> , <i>Proteus mirabilis</i>
Cystic fibrosis	<i>Pseudomonas aeruginosa</i> (infects adults), <i>Staphylococcus aureus</i> (infects children)
Breast implant infections	<i>S. aureus</i> and <i>S. epidermidis</i> , <i>Pseudomonas aeruginosa</i>
Catheter-Related Bloodstream Infection (CRBI)	<i>Staphylococcus epidermidis</i> , <i>Staphylococcus aureus</i> , <i>Enterococcus</i> species, and <i>Candida</i> species (<i>C. albicans</i> and <i>C. parapsilosis</i>)
Contact Lens Infections	Bacterial species- <i>Staphylococcus aureus</i> , <i>Pseudomonas aeruginosa</i> , and <i>Serratia marcescens</i> . Fungal species such as <i>Candida albicans</i> , <i>Aspergillus</i> , and <i>Fusarium</i> species
Periprosthetic Joint Infection (PJI)	<i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , and <i>Enterococcus</i>
Infective endocarditis	<i>Streptococci</i> , <i>Staphylococci</i> , <i>Enterococci</i>

Biofilms, known as BAIs (biofilm-associated infections), present a significant hurdle in disease treatment due to their resistance to antibiotics, primarily rooted in their genetic makeup. Multidrug resistance (MDR) genes identified across bacterial species impede drug action mechanisms, exacerbating antibiotic resistance. Common resistance mechanisms encompass mutation-induced alterations in target proteins, enzymatic deactivation of drugs, gene acquisition from less susceptible species, and evasion of drug penetration to target sites.

However, it's important to note that not all biofilms are detrimental. Some microbial biofilms play a crucial role in maintaining human well-being, such as probiotic biofilms. These biofilms harbor beneficial bacteria essential for gut health, promoting tissue growth and bolstering the immune system. Common examples of bacteria found in probiotic biofilms include *Lactobacillus*, *Bacillus laterosporus*, and *Pediococcus acidilactici*.

Unveiling Antimicrobial Resistance Mechanisms in Biofilms

Understanding antimicrobial resistance (AMR) within biofilms is pivotal due to its profound impact on treatment efficacy. Bacteria residing in biofilms can exhibit an astonishing 10 to 1,000-fold increase in antibiotic resistance compared to their planktonic counterparts.

Three primary mechanisms contribute to antibiotic resistance in biofilms:

1. Surface Resistance:

The initial hurdle occurs at the biofilm surface, where antibiotics encounter a complex matrix of exopolysaccharides, DNA, and proteins. This intricate structure impedes antibiotic penetration, resulting in reduced diffusion and swift deactivation at the surface. However, the extent of this mechanism's contribution to AMR varies among biofilms and necessitates further investigation.

2. Resistance within Biofilm Microenvironments:

Deeper within the biofilm, antibiotics confront a hostile microenvironment characterized by metabolic byproducts, nutrient accumulation, and diminished oxygen levels. These conditions affect antibiotic efficacy differently based on their chemical properties and mode of action. For instance, low

oxygen levels diminish the potency of specific antibiotics such as tobramycin and ciprofloxacin, while pH fluctuations influence aminoglycoside activity.

3. Resistance of Bacterial "Persister" Cells:

In the depths of the biofilm layers, a subset of bacteria adopts a persister phenotype, entering a dormant state resistant to antibiotics. These persister cells remain dormant in the presence of antibiotics, exhibiting transient resistance without genetic alterations. Upon exiting the biofilm or resuming division, persister cells regain susceptibility to antibiotics.

Addressing the Challenge of Biofilms

Addressing biofilms presents a formidable challenge, with potential implications for increased infection rates and associated morbidity and mortality. The widespread use of antibiotics in treating biofilm-associated infections has spurred the emergence of highly virulent, antibiotic-resistant bacteria, necessitating innovative eradication approaches.

Strategies for Biofilm Control

- **Surface Engineering:** Designing surfaces to impede bacterial adhesion and biofilm formation.
- **Preoperative and Postoperative Measures:** Implementing rigorous protocols before and after medical procedures to minimize biofilm-related infections.
- **Antimicrobial Coatings:** Applying coatings with antimicrobial properties to medical devices and implants to deter bacterial attachment.
- **Early Intervention:** Intervening at the inception of biofilm formation using antibacterial agents, dietary supplements, and environmental modifications.
- **Biofilm Reduction and Elimination:** Despite the challenges posed by mature biofilms, their growth can be managed and potentially eradicated using agents targeting extracellular polymeric substances (EPS), dissociation drivers, vaccination, and mechanical removal.
- **Multifaceted Approaches:** Employing a combination of physical, biological, medicinal, and integrated techniques in clinical settings to dissolve mature biofilms.

A concerted effort is essential to develop therapeutic agents targeting the biofilm phenotype and community signaling to effectively control biofilms and enhance patient outcomes. Combination strategies involving mechanical disruption, immune modulation, and antimicrobial agents hold promise in eradicating biofilms and combating AMR.

REFERENCES

1. Rather, M. A., Gupta, K., & Mandal, M. (2021). Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. *Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]*, 52(4), 1701–1718.
2. Vestby, L. K., Gronseth, T., Simm, R., & Nesse, L. L. (2020). Bacterial Biofilm and its Role in the Pathogenesis of Disease. *Antibiotics (Basel, Switzerland)*, 9(2), 59.
3. Sharma, D., Misba, L. & Khan, A.U. Antibiotics versus biofilm: an emerging battleground in microbial communities. *Antimicrob Resist Infect Control* 8, 76 (2019).
4. Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial Biofilm: A Review on Formation, Infection, Antibiotic Resistance, Control Measures, and Innovative Treatment. *Microorganisms*. 2023; 11(6):1614.
5. Rodney M. Donlan, Biofilm Formation: A Clinically Relevant Microbiological Process, *Clinical Infectious Diseases*, Volume 33, Issue 8, 15 October 2001, Pages 1387–1392